bioRxiv · 10.1101/560482
An omentum-inspired 3D PEG hydrogel for identifying ECM drivers of drug resistant ovarian cancer
Abstract
Ovarian cancer (OvCa) is a challenging disease to treat due to poor screening techniques and late diagnosis. There is an urgent need for additional therapy options, as patients recur in 70% of cases. The limited availability of clinical treatment options could be a result of poor predictions in early stage drug screens on standard tissue culture polystyrene (TCPS). TCPS does not capture the mechanical and biochemical cues that cells experience in vivo, which can impact how cells will respond to a drug. Therefore, an in vitro model that captures some of the microenvironment features that the cells experience in vivo could provide better insights into drug response. In this study, we formed 3D multicellular tumor spheroids (MCTS) in microwells, and encapsulated them in 3D omentum-inspired hydrogels. SKOV-3 MCTS were resistant to Paclitaxel in our 3D hydrogels compared to a monolayer on TCPS. Toward clinical application, we tested cells from patients (ovarian carcinoma ascites spheroids (OCAS)), and drug responses predicted by using the 3D omentum-inspired hydrogels correlated with the reported pathology reports of those same patients. Additionally, we observed the presence of collagen production around the encapsulated SKOV-3 MCTS, but not on TCPS. Our results demonstrated that our 3D omentum-inspired hydrogel is an improved in vitro drug testing platform to study OvCa drug response for patient-derived cells, and helped us identify collagen 3 as a potential driver of Paclitaxel resistance.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Brooks, E. A., Gencoglu, M. F., Corbett, D. C., Stevens, K. R., Peyton, S.. 2019-02-25. An omentum-inspired 3D PEG hydrogel for identifying ECM drivers of drug resistant ovarian cancer. https://doi.org/10.1101/560482
Cite the original work for its findings. Save a collection to share your selection of sources.